Details of the Drug
General Information of Drug (ID: DM9G7DT)
Drug Name |
1,2-Dihydro-indazol-3-one
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
1H-Indazol-3-ol; 3-Indazolinone; 7364-25-2; 1H-indazol-3(2H)-one; 100922-96-1; Indazolinone; 3-Hydroxy-1H-indazole; 3-Hydroxyindazole; 1,2-dihydroindazol-3-one; 1,2-Dihydro-3H-indazol-3-one; 3-Oxo-1,2-indazole; 3H-Indazol-3-one, 1,2-dihydro-; 3-Indazolone; 2H-Indazol-3-ol; hydroxyindazole; 2,3-Dihydro-1H-indazol-3-one; NSC 9352; UNII-8E254S9S1R; CCRIS 6800; EINECS 230-904-2; CHEMBL276725; SWEICGMKXPNXNU-UHFFFAOYSA-N; 8E254S9S1R; MFCD00005685; 1H-2-hydroindazol-3-one; benzopyrazolone; 1,2-Dihydro-indazol-3-one; 3-Oxoindazoline
|
||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||
Structure | |||||||||||||||||||||||
3D MOL | 2D MOL | ||||||||||||||||||||||
#Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 134.14 | |||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | 1.2 | ||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 0 | ||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 2 | ||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 2 | ||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Discovery agent | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||